USC Keck School of Medicine


USC Keck Medicine Launches Clinical Trial to Study Baricitinib, an Anti-Inflammatory, as COVID-19 Treatment for Severe Cases

Keck Medicine of USC physicians are launching a clinical trial to evaluate the efficacy and safety of baricitinib, an anti-inflammatory drug approved by the Food and Drug Administration to treat rheumatoid arthritis, as a possible treatment for patients with moderate...

Pin It on Pinterest